Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-568.73% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-85.99% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
1,265.92% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
61.49% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-95.55% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
191.97% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
103.60% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
42.41% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Bristol Myers Squibb |
244.56 Mn |
-10.21 Bn |
8.07 Bn |
-227.06% |
| Date | Value |
|---|
| Mar 31, 2026 |
-227.06% |
| Dec 31, 2025 |
-311.96% |
| Sep 30, 2025 |
105.20% |
| Jun 30, 2025 |
153.32% |
| Mar 31, 2025 |
121.59% |
| Dec 31, 2024 |
-32.84% |
| Sep 30, 2024 |
285.59% |
| Jun 30, 2024 |
-390.41% |
| Mar 31, 2024 |
-637.93% |
| Dec 31, 2023 |
204.24% |
| Sep 30, 2023 |
72.11% |
| Jun 30, 2023 |
60.27% |
| Mar 31, 2023 |
83.39% |
| Dec 31, 2022 |
159.27% |
| Sep 30, 2022 |
-217.01% |
| Jun 30, 2022 |
-2,768.97% |
| Mar 31, 2022 |
51.69% |
| Dec 31, 2021 |
109.87% |
| Sep 30, 2021 |
570.92% |
| Jun 30, 2021 |
-98.57% |
